Document:

GO2PHARMACY, INC.

                         UTENDAHL CAPITAL PARTNERS, L.P.
                ( on behalf of the underwriters of the offering)

                                  UNDERWRITERS'

                                WARRANT AGREEMENT

                  UNDERWRITER'S WARRANT AGREEMENT dated as of , 2000 by and
among GO2PHARMACY, INC. (the "Company") and UTENDAHL CAPITAL PARTNERS, L.P.
("Underwriter" or "Utendahl") (Utendahl and the other Underwriters for whom
Utendahl is acting as representative are collectively referred to as the
("Underwriters").

                              W I T N E S S E T H:
                               -------------------

         WHEREAS, the Company proposes to issue to the Underwriters 100,000
warrants (each a "Underwriters' Warrant") each to purchase a share of the
Company's common stock, par value $.01 per share (the "Common Stock").

         WHEREAS, the Underwriter has agreed, pursuant to the underwriting
agreement (the "Underwriting Agreement") dated September , 2000, by and between
the Underwriter and the Company, to act as the Underwriter in connection with
the Company's proposed public offering (the "Public Offering") of 1,000,000
shares of Common Stock (the "Offering Securities"); and

         WHEREAS, the Underwriters' Warrants to be issued pursuant to this
Agreement will be issued on the Closing Date (as such term is defined in the
Underwriting Agreement) by the Company to the Underwriters in consideration for,
and as part of, the Underwriters' compensation in connection with the
Underwriters' acting as the Underwriters pursuant to the Underwriting Agreement;

         NOW, THEREFORE, in consideration of the premises, the payment by the
Underwriter to the Company of Ten Dollars ($10.00), the agreements herein set
forth and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties hereto agree as follows:

         1. GRANT. The Holder (as defined in Section 3 below) is hereby granted
the right to purchase, at any time from , 2001 until 5:00 p.m., New York time,
September , 2005, up to 100,000 shares of Common Stock, at an initial purchase
price (subject to adjustment as provided in Section 8 hereof) of $9.60 per share
of Common Stock (165% of the per share public offering price), subject to the
terms and conditions of this Agreement. The securities issuable, upon exercise
of the Underwriters' Warrant are sometimes referred to herein as the
"Underwriters' Securities."

         2. WARRANT CERTIFICATES. The warrant certificate (the "Underwriters'
Warrant Certificate") to be delivered pursuant to this Agreement shall be in the
form set forth in Exhibit A attached hereto and made a part hereof, with such
appropriate insertions, omissions, substitutions, and other variations as
required or permitted by this Agreement.

         3.       EXERCISE OF UNDERWRITERS' WARRANT.

                  (a) The Underwriters' Warrant is exercisable during the term
set forth in Section 1 hereof payable by certified or cashier's check or money
order in lawful money of the United States. Upon surrender of Underwriters'
Warrant Certificate with the annexed Form of Election to Purchase duly executed,
together with payment of the Purchase Price (as hereinafter defined) for the
Underwriters' Securities (and such other amounts, if any, arising pursuant to
Section 4 hereof) at the Company's principal office currently located at 6950
Bryan Dairy Road, Largo, Florida 33777, the registered holder of an
Underwriters' Warrant Certificate ("Holder" or "Holders") shall be entitled to
receive a certificate or certificates for the Underwriters' Securities so
purchased. The purchase rights represented by each Underwriters' Warrant
Certificate are exercisable at the option of the Holder or Holders thereof, in
whole or in part as to Underwriters' Securities. The Underwriters' Warrant may
be exercised to purchase all or any part of the Underwriters' Securities
represented thereby. In the case of the purchase of less than all the
Underwriters' Securities purchasable on the exercise of the Underwriters'
Warrant represented by an Underwriters' Warrant Certificate, the Company shall
cancel the Underwriters' Warrant Certificate represented thereby upon the

<PAGE>

surrender thereof and shall execute and deliver a new Underwriters' Warrant
Certificate of like tenor for the balance of the Underwriters' Securities
purchasable thereunder.

                  (b) In lieu of the payment of cash upon exercise of the
Underwriters' Warrant as provided in Section 3(a), the Holder may exercise the
Underwriters' Warrant by surrendering the Underwriters' Warrant Certificate at
the principal office of the Company, accompanied by a notice stating (i) the
Holder's intent to effect such exercise by an exchange, (ii) Common Stock to be
issued upon the exchange, (iii) whether Underwriters' Warrants are to be
surrendered in connection with the exchange, and (iv) the date on which the
Holder requests that such exchange is to occur. The Purchase Price for the
Underwriters' Securities to be acquired in the exchange shall be paid by the
surrender as indicated in the notice, of Underwriters' Warrants, having a
"Value", as defined below, equal to the Purchase Price. "Value" as to each
Underwriters' Warrant shall mean the difference between the "Market Price", as
hereinafter defined, of a share of Common Stock and the then Purchase Price for
a share of Common Stock.

                  By way of example of the application of the formula, assume
that the Market Price of the Common Stock is $8.00, the Purchase Price of the
Underwriters' Warrant is $6.00. On such assumptions, the Value of a
Underwriters' Warrant is $2.00 ($8.00-$6.00) and therefore for each three
Underwriters' Warrants surrendered, the Holder could acquire one share of Common
Stock in the exchange. Notwithstanding the example, the Holder shall not be
limited to exchanging Underwriters' Warrants for Common Stock.

         The Warrant Exchange shall take place on the date specified in the
notice or if the date the notice is received by the Company is later than the
date specified in the notice, on the date the notice is received by the Company.

         4. ISSUANCE OF CERTIFICATES. Upon the exercise of the Underwriters'
Warrant and payment of the Purchase Price therefor, the issuance of certificates
representing the Underwriters' Securities or other securities, properties or
rights underlying such Underwriters' Warrant, shall be made forthwith (and in
any event within five (5) business days thereafter) without further charge to
the Holder thereof, and such certificates shall (subject to the provisions of
Sections 5 and 7 hereof) be issued in the name of, or in such names as may be
directed by, the Holder thereof; provided, however, that the Company shall not
be required to pay any tax which may be payable in respect of any transfer
involved in the issuance and delivery of any such certificates in a name other
than that of the Holder, and the Company shall not be required to issue or
deliver such certificates unless or until the person or persons requesting the
issuance thereof shall have paid to the Company the amount of such tax or shall
have established to the satisfaction of the Company that such tax has been paid.
The Underwriters' Warrant Certificates and the certificates representing the
Underwriters' Securities or other securities, property or rights (if such
property or rights are represented by certificates) shall be executed on behalf
of the Company by the manual or facsimile signature of the then present Chairman
or Vice Chairman of the Board of Directors or President or Vice President of the
Company, attested to by the manual or facsimile signature of the then present
Secretary or Assistant Secretary or Treasurer or Assistant Treasurer of the
Company. The Underwriters' Warrant Certificates shall be dated the date of
issuance thereof by the Company upon initial issuance, transfer or exchange.

         5. RESTRICTION ON TRANSFER OF UNDERWRITERS' WARRANT. The Holder of an
Underwriters' Warrant Certificate (and its Permitted Transferee, as defined
below), by its acceptance thereof, covenants and agrees that the Underwriters'
Warrant may be sold, transferred, assigned, hypothecated or otherwise disposed
of, in whole or in part, until , 2001 (one year following the effective date of
the Public Offering), only to officers and partners of the Underwriters, or any
Public Offering selling group member and their respective officers and partners,
("Permitted Transferees"). Thereafter the Underwriters' Warrant may be
transferred, assigned, hypothecated or otherwise disposed of in compliance with
applicable law.

         6.       PURCHASE PRICE.

                  (a) INITIAL AND ADJUSTED PURCHASE PRICE. Except as otherwise
provided in Section 8 hereof, the initial purchase price of the Underwriters'
Securities shall be $13.20 per share of Common Stock (165% of the per share
public offering price). The adjusted purchase price shall be the price which
shall result from time to time from any and all adjustments of the initial
purchase price in accordance with the provisions of Section 8 hereof.

<PAGE>

                  (b) PURCHASE PRICE. The term "Purchase Price" herein shall
mean the initial purchase price or the adjusted purchase price, depending upon
the context.

         7.       REGISTRATION RIGHTS.

                  (a) REGISTRATION UNDER THE SECURITIES ACT OF 1933 AS AMENDED
("ACT"). The Underwriters' Warrant may have not been registered under the Act.
The Underwriters' Warrant Certificates may bear the following legend:

                  "The securities represented by this certificate have not been
registered under the Securities Act of 1933 (the "Act"), and may not be offered
for sale or sold except pursuant to (i) an effective registration statement
under the Act, or (ii) an opinion of counsel, if such opinion and counsel shall
be reasonably satisfactory to counsel to the issuer, that an exemption from
registration under the Act is available".

                  (b) DEMAND REGISTRATION. (1) At any time commencing on the
first anniversary of and expiring on the fifth anniversary of the effective date
of the Company's Registration Statement relating to the Public Offering (the
"Effective Date"), the Holders of a Majority (as hereinafter defined) in
interest of the Underwriters' Warrant, or the Majority in interest of the
Underwriters' Securities (assuming the exercise of all of the Underwriters'
Warrant) shall have the right, exercisable by written notice to the Company, to
have the Company prepare and file with the U.S. Securities and Exchange
Commission (the "Commission"), on one (1) occasion, a registration statement on
Form SB-2, S-1 or other appropriate form, and such other documents, including a
prospectus, as may be necessary in the opinion of both counsel for the Company
and counsel for the Holders, in order to comply with the provisions of the Act,
so as to permit a public offering and sale, of the Underwriters' Securities by
such Holders and any other Holders of the Underwriters' Warrant and/or the
Underwriters' Securities who notify the Company within fifteen (15) business
days after receipt of the notice described in Section 7(b)(2). The Holders of
the Underwriters' Warrant may demand registration prior to exercising the
Underwriters' Warrant, and may pay such exercise price from the proceeds of such
public offering.

         (2) The Company covenants and agrees to give written notice of any
registration request under this Section 7(b) by any Holders to all other
registered Holders of the Underwriters' Warrant and the Underwriters' Securities
within ten (10) calendar days from the date of the receipt of any such
registration request.

         (3) For purposes of this Agreement, the term "Majority" in reference to
the Holders of the Underwriters' Warrant or Underwriters' Securities, shall mean
in excess of fifty percent (50%) of the then outstanding Underwriters' Warrant
or Underwriters' Securities that (i) are not held by the Company, an affiliate,
officer, creditor, employee or agent thereof or any of their respective
affiliates, members of their family, persons acting as nominees or in
conjunction therewith, or (ii) have not been resold to the public pursuant to a
registration statement filed with the Commission under the Act.

                  (c) PIGGYBACK REGISTRATION. (1) If, at any time within the
period commencing on the first anniversary and expiring on the sixth anniversary
of the Effective Date, the Company should file a registration statement with the
Commission under the Act (other than in connection with a merger or other
business combination transaction or pursuant to Form S-8), it will give written
notice at least twenty (20) calendar days prior to the filing of each such
registration statement to the Underwriter and to all other Holders of the
Underwriters' Warrant and/or the Underwriters' Securities of its intention to do
so. If an Underwriter or other Holders of the Underwriters' Warrant and/or the
Underwriters' Securities notify the Company within fifteen (15) calendar days
after receipt of any such notice of its or their desire to include any
Underwriters' Securities in such proposed registration statement, the Company
shall afford the Underwriter and such Holders of the Underwriters' Warrant
and/or Underwriters' Securities the opportunity to have any such Underwriters'
Securities registered under such registration statement. Notwithstanding the
provisions of this Section 7(c)(1) and the provisions of Section 7(d), the
Company shall have the right at any time after it shall have given written
notice pursuant to this Section 7(c)(1) (irrespective of whether a written
request for inclusion of any such securities shall have been made) to elect not
to file any such proposed registration statement, or to withdraw the same after
the filing but prior to the effective date thereof.

                           (2) If the managing underwriter of an offering to
which the above piggyback rights

<PAGE>

apply, in good faith and for valid business reasons, objects to such rights,
such objection shall preclude such inclusion.

                  (d) COVENANTS OF THE COMPANY WITH RESPECT TO REGISTRATION. In
connection with any registrations under Sections 7(b) and 7(c) hereof, the
Company covenants and agrees as follows:

                                    (1) The Company shall use its best efforts
to file a registration statement within thirty (30) calendar days of receipt of
any demand therefor pursuant to Section 7(b); provided, however, that the
Company shall not be required to produce audited or unaudited financial
statements for any period prior to the date such financial statements are
required to be filed in a report on Form 10-KSB or Form 10-QSB, as the case may
be. The Company shall use its best efforts to have any registration statement
declared effective at the earliest possible time, and shall furnish each Holder
desiring to sell Underwriters' Securities such number of prospectuses as shall
reasonably be requested.

                                    (2) The Company shall pay all costs
(excluding fees and expenses of Holders' counsel and any underwriting discounts
or selling fees, expenses or commissions), fees and expenses in connection with
any registration statement filed pursuant to Sections 7(b) and 7(c) hereof
including, without limitation, the Company's legal and accounting fees, printing
expenses, blue sky fees and expenses.

                                    (3) The Company will use its best efforts to
qualify or register the Underwriters' Securities included in a registration
statement for offering and sale under the securities or blue sky laws of such
states as reasonably are requested by the Holders, provided that the Company
shall not be obligated to execute or file any general consent to service of
process or to qualify as a foreign corporation to do business under the laws of
any such jurisdiction.

                                    (4) The Company shall indemnify the Holders
of the Underwriters' Securities to be sold pursuant to any registration
statement and each person, if any, who controls such Holders within the meaning
of Section 15 of the Act or Section 20(a) of the Securities Exchange Act of 1934
(the "Exchange Act"), against all loss, claim, damage, expense or liability
(including all expenses reasonably incurred in investigating, preparing or
defending against any claim whatsoever) to which any of them may become subject
under the Act, the Exchange Act or otherwise, arising from such registration
statement, but only to the same extent and with the same effect as the
provisions pursuant to which the Company has agreed to indemnify the Underwriter
contained in Section 8 of the Underwriting Agreement.

                                    (5) The Holders of the Underwriters'
Securities to be sold pursuant to a registration statement, and their successors
and assigns, shall indemnify the Company, its officers and directors and each
person, if any, who controls the Company within the meaning of Section 15 of the
Act or Section 20(a) of the Exchange Act, against all loss, claim, damage or
expense or liability to which they may become subject under the Act, the
Exchange Act or otherwise, arising from information furnished by or on behalf of
such Holders, or their successors or assigns, for specific inclusion in such
registration statement to the same extent and with the same effect as the
provisions contained in Section 8 of the Underwriting Agreement pursuant to
which the Underwriter has agreed to indemnify the Company.

                                    (6) Nothing contained in this Agreement
shall be construed as requiring the Holders to exercise their Underwriters'
Warrant prior to the initial filing of any registration statement or the
effectiveness thereof, provided that such Holders have made arrangements
reasonably satisfactory to the Company to pay the exercise price from the
proceeds of such offering.

                                    (7) The Company shall furnish to each
Underwriter for the offering, if any, such documents as such Underwriter may
reasonably require.

                                    (8) The Company shall as soon as practicable
after the effective date of the registration statement, and in any event within
15 months thereafter, make "generally available to its security holders" (within
the meaning of Rule 158 under the Act) an earnings statement (which need not be
audited) complying with Section 11(a) of the Act and covering a period of at
least 12 consecutive months beginning after the

<PAGE>

effective date of the registration statement.

                                    (9) The Company shall deliver promptly to
each Holder participating in the offering requesting the correspondence
described below and any managing Underwriter copies of all correspondence
between the Commission and the Company, its counsel or auditors with respect to
the registration statement and permit each Holder and Underwriter to do such
investigation, upon reasonable advance notice, with respect to information
contained in or omitted from the registration statement as it deems reasonably
necessary to comply with applicable securities laws or rules of the National
Association of Securities Dealers, Inc. ("NASD"). Such investigation shall
include access to books, records and properties and opportunities to discuss the
business of the Company with its officers and independent auditors, all to such
reasonable extent and at such reasonable times and as often as any such Holder
shall reasonably request.

                                    (10) The Company shall enter into an
underwriting agreement with the managing underwriter selected for such
underwriting by Holders holding a Majority of the Underwriters' Securities
requested to be included in such underwriting, provided, however that such
managing underwriter shall be reasonably acceptable to the Company, except that
in connection with an offering for which the Holders have piggyback rights, the
Company shall have the sole right to select the managing underwriter or
underwriters. Such underwriting agreement shall be satisfactory in form and
substance to the Company, a Majority of such Holders (in respect of a
registration under Section 7(b) only) and such managing underwriter, and shall
contain such representations, warranties and covenants by the Company and such
other terms as are customarily contained in agreements of that type. The Holders
shall be parties to any underwriting agreement relating to an underwritten sale
of their Underwriters' Securities. Such Holders shall not be required to make
any representations or warranties to or agreements with the Company or the
underwriters except as they may relate to such Holders and their intended
methods of distribution.

         8.       ADJUSTMENTS TO PURCHASE PRICE AND NUMBER OF SECURITIES.

                           (a) COMPUTATION OF ADJUSTED PURCHASE PRICE. Except as
hereinafter provided, in case the Company shall at any time after the date
hereof issue or sell any shares of Common Stock (other than the issuances
referred to in Section 8(g) hereof), including shares held in the Company's
treasury, for a consideration per share less than the "Market Price" (as defined
in Section 8(a)(6) hereof) per share of Common Stock on the date immediately
prior to the issuance or sale of such shares, or without consideration, then
forthwith upon any such issuance or sale, the Purchase Price of the Common Stock
shall (until another such issuance or sale) be reduced to the price (calculated
to the nearest full cent) determined by dividing (1) the product of (a) the
Purchase Price in effect immediately before such issuance or sale and (b) the
sum of (i) the total number of shares of Common Stock outstanding immediately
prior to such issuance or sale, and (ii) the number of shares determined by
dividing (A) the aggregate consideration, if any, received by the Company upon
such sale or issuance, by (B) the Market Price, and by (2) the total number of
shares of Common Stock outstanding immediately after such issuance or sale
provided, however, that in no event shall the Purchase Price be adjusted
pursuant to this computation to an amount in excess of the Purchase Price in
effect immediately prior to such computation, except in the case of a
combination of outstanding shares of Common Stock, as provided by Section 8(c)
hereof.

                  For the purposes of this Section 8, the term "Purchase Price"
shall mean the Purchase Price of the Common Stock forming a part of the
Underwriters' Securities set forth in Section 6 hereof, as adjusted from time to
time pursuant to the provisions of this Section 8.

                  For the purposes of any computation to be made in accordance
with this Section 8(a), the following provisions shall be applicable:

         (1) In case of the issuance or sale of shares of Common Stock (or of
other securities deemed hereunder to involve the issuance or sale of shares of
Common Stock) for a consideration part or all of which shall be cash, the amount
of the cash consideration therefor shall be deemed to be the amount of cash
received by the Company for such shares (or, if shares of Common Stock are
offered by the Company for subscription, the subscription price, or, if such
securities shall be sold to Underwriters or dealers for public offering without
a

<PAGE>

subscription offering, the initial public offering price) before deducting
therefrom any compensation paid or discount allowed in the sale, underwriting or
purchase thereof by Underwriters or dealers or others performing similar
services, or any expenses incurred in connection therewith.

           (2) In case of the issuance or sale (otherwise than as a dividend or
other distribution on any stock of the Company, and otherwise than on the
exercise of options, rights or warrants or the conversion or exchange of
convertible or exchangeable securities) of shares of Common Stock (or of other
securities deemed hereunder to involve the issuance or sale of shares of Common
Stock) for a consideration part or all of which shall be other than cash, the
amount of the consideration therefor other than cash shall be deemed to be the
value of such consideration as determined in good faith by the Board of
Directors of the Company.

         (3) Shares of Common Stock issuable by way of dividend or other
distribution on any stock of the Company shall be deemed to have been issued
immediately after the opening of business on the day following the record date
for the determination of stockholders entitled to receive such dividend or other
distribution and shall be deemed to have been issued without consideration.

         (4) The reclassification of securities of the Company other than shares
of Common Stock into securities including shares of Common Stock shall be deemed
to involve the issuance of such shares of Common Stock for a consideration other
than cash immediately prior to the close of business on the date fixed for the
determination of security holders entitled to receive such shares, and the value
of the consideration allocable to such shares of Common Stock shall be
determined as provided in Section 8(a)(2).

           (5) The number of shares of Common Stock at any one time outstanding
shall include the aggregate number of shares of Common Stock issued or issuable
(subject to readjustment upon the actual issuance thereof) upon the exercise of
options, rights or warrants and upon the conversion or exchange of convertible
or exchangeable securities.

           (6) As used herein in the phrase "Market Price" at any date shall be
deemed to be the last reported sale price, or, in the case no such reported sale
takes place on such day, the average of the last reported sales prices for the
last three (3) trading days, in either case as officially reported by the
principal securities exchange on which the Common Stock is listed or admitted to
trading, or, if the Common Stock is not listed or admitted to trading on any
national securities exchange, the average closing bid price as furnished by the
NASD through the NASD Automated Quotation System ("NASDAQ") or similar
organization if NASDAQ is no longer reporting such information, or if the Common
Stock is not quoted on NASDAQ, as determined in good faith by resolution of the
Board of Directors of the Company, based on the best information available to
it.

                           (b) OPTIONS, RIGHTS, WARRANTS AND CONVERTIBLE AND
EXCHANGEABLE SECURITIES. Except in the case of the Company issuing rights to
subscribe for shares of Common Stock distributed to all the stockholders of the
Company and Holders of Underwriters' Warrant pursuant to Section 8(i) hereof, if
the Company shall at any time after the date hereof issue options, rights or
warrants to purchase shares of Common Stock, or issue any securities convertible
into or exchangeable for shares of Common Stock (other than the issuances
referred to in Section 8(g) hereof), (i) for a consideration per share less than
the Market Price (including the issuance thereof without consideration such as
by way of dividend or other distribution), or (ii) without consideration, the
Purchase Price in effect immediately prior to the issuance of such options,
rights or warrants, or such convertible or exchangeable securities, as the case
may be, shall be reduced to a price determined by making a computation in
accordance with the provisions of Section 8(a) hereof, provided that:

                                    (1) The aggregate maximum number of shares
of Common Stock issuable or that may become issuable under such options, rights
or warrants (assuming exercise in full even if not then currently exercisable or
currently exercisable in full) shall be deemed to be issued and outstanding at
the time such options, rights or warrants were issued, and for a consideration
equal to the minimum purchase price per share provided for in such options,
rights or warrants at the time of issuance, plus the consideration (determined
in the same manner as consideration received on the issue or sale of shares in
accordance with the terms of the Underwriters' Warrant), if any, received by the
Company for such options, rights or warrants; provided, however, that upon the
expiration or other termination of such options, rights or warrants, if any
thereof shall not have been

<PAGE>
exercised, the number of shares of Common Stock deemed to be issued and
outstanding pursuant to this Section 8(b)(1) (and for the purposes of Section
8(a)(5) hereof) shall be reduced by such number of shares as to which options,
warrants and/or rights shall have expired or terminated unexercised, and such
number of shares shall no longer be deemed to be issued and outstanding, and the
Purchase Price then in effect shall forthwith be readjusted and thereafter be
the price which it would have been had adjustment been made on the basis of the
issuance only of shares actually issued or issuable upon the exercise of those
options, rights or warrants as to which the exercise rights shall not be expired
or terminated unexercised.

                                    (2) The aggregate maximum number of shares
of Common Stock issuable upon conversion or exchange of any convertible or
exchangeable securities (assuming conversion or exchange in full even if not
then currently convertible or exchangeable in full) shall be deemed to be issued
and outstanding at the time of issuance of such securities, and for a
consideration equal to the consideration (determined in the same manner as
consideration received on the issue or sale of shares of Common Stock in
accordance with the terms of the Underwriters' Warrant) received by the Company
for such securities, plus the minimum consideration, if any, receivable by the
Company upon the conversion or exchange thereof; provided, however, that upon
the expiration or other termination of the right to convert or exchange such
convertible or exchangeable securities (whether by reason or redemption or
otherwise), the number of shares deemed to be issued and outstanding pursuant to
this Section 8(b)(2) (and for the purpose of Section 8(a)(5) hereof) shall be
reduced by such number of shares as to which the conversion or exchange rights
shall have expired or terminated unexercised, and such number of shares shall no
longer be deemed to be issued and outstanding and the Purchase Price then in
effect shall forthwith be readjusted and thereafter be the price which it would
have been had adjustment been made on the basis of the issuance only of the
shares actually issued or issuable upon the conversion or exchange of those
convertible or exchangeable securities as to which the conversion or exchange
rights shall not have expired or terminated unexercised.

                                    (3) If any change shall occur in the price
per share provided for in any of the options, rights or warrants referred to in
Section 8(b)(1), or in the price per share at which the securities referred to
in Section 8(b)(2) are convertible or exchangeable, and if a change in the
Purchase Price has not occurred by reason of the event giving rise to the change
in the price per share of such other options, rights, warrants, or convertible
or exchangeable securities, such options, rights or warrants or conversion or
exchange rights, as the case may be, to the extent not theretofore exercised,
the shall be deemed to have expired or terminated on the date when such price
change became effective in respect of shares not theretofore issued pursuant to
the exercise or conversion or exchange thereof, and the Company shall be deemed
to have issued upon such date new options, rights or warrants or convertible or
exchangeable securities at the new price in respect of the number of shares
issuable upon the exercise of such options, rights or warrants or the conversion
or exchange of such convertible or exchangeable securities.

                           (c) SUBDIVISION AND COMBINATION. In case the Company
shall at any time issue any shares of Common Stock in connection with a stock
dividend in shares of Common Stock or subdivide or combine the outstanding
shares of Common Stock, the Purchase Price shall forthwith be proportionately
decreased in the case of a stock dividend or a subdivision or increased in the
case of combination.

                           (d) ADJUSTMENT IN NUMBER OF SECURITIES. Upon each
adjustment of the Purchase Price pursuant to the provisions of this Section 8,
the number of Underwriters' Securities issuable upon the exercise of the
Underwriters' Warrant shall be adjusted to the nearest whole share by
multiplying a number equal to the Purchase Price in effect immediately prior to
such adjustment by the number of Underwriters' Securities issuable upon exercise
of the Underwriters' Warrant immediately prior to such adjustment and dividing
the product so obtained by the adjusted Purchase Price.

                           (e) DEFINITION OF COMMON STOCK. For the purpose of
this Agreement, the term "Common Stock" shall mean the class of stock designated
as Common Stock in the Certificate of Incorporation, of the Company as it may be
amended as of the date hereof.

                           (f) RECLASSIFICATION, MERGER OR CONSOLIDATION. The
Company will not merge, reorganize or take any other action which would
terminate the Underwriters' Warrant without first making adequate

<PAGE>

provision for the Underwriters' Warrant. In case of any reclassification or
change of the outstanding shares of Common Stock issuable upon exercise of the
outstanding warrants (other than a change in par value to no par value, or from
nor par value to par value, or as a result of a subdivision or combination), or
in case of any consolidation of the Company with, or merger of the Company with,
or merger of the Company into, another corporation (other than a consolidation
or merger in which the Company is the continuing corporation and which does not
result in any reclassification or change of the outstanding Common Stock except
a change as a result of a subdivision or combination of such shares or a change
in par value, as aforesaid), or in the case of a sale or conveyance to another
corporation or other entity of the property of the Company as an entirety or
substantially as an entirety, the Holders of each Underwriters' Warrant then
outstanding or to be outstanding shall have the right thereafter (until the
expiration of such Underwriters' Warrant) to purchase, upon exercise of such
Underwriters' Warrant, the kind and number of shares of stock and other
securities and property receivable upon such reclassification, change,
consolidation, merger, sale or conveyance as if the Holders were the owner of
the shares of Common Stock underlying the Underwriters' Warrant immediately
prior to any such events at a price equal to the product of (x) the number of
shares issuable upon exercise of the Underwriters' Warrant and (y) the Purchase
Price in effect immediately prior to the record date for such reclassification,
change, consolidation, merger, sale or conveyance, as if such Holders had
exercised the Underwriters' Warrant. In the event of a consolidation, merger,
sale or conveyance of property, the corporation formed by such consolidation or
merger, or acquiring such property, shall execute and deliver to the Holders a
supplemental Underwriters' warrant agreement to such effect. Such supplemental
Underwriters' warrant agreement shall provide for adjustments which shall be
identical to the adjustment provided for in this Section 8. The provisions of
this Section 8(f) shall similarly apply to successive consolidations or mergers.

                           (g) NO ADJUSTMENT OF PURCHASE PRICE IN CERTAIN CASES.
No adjustment of the Purchase Price shall be made:

                                    (1) Upon the issuance or sale of (i) the
Underwriters' Warrant or the securities underlying the Underwriters' Warrant,
(ii) the securities sold pursuant to the Public Offering (including those sold
upon exercise of the Underwriters' over-allotment option), or (iii) the shares
issuable pursuant to the options, warrants, rights, stock purchase agreements or
convertible or exchangeable securities outstanding or in effect on the date
hereof as described in the prospectus relating to the Public Offering.

                                    (2) If the amount of said adjustments shall
aggregate less than two ($.02) cents for one (1) share of Common Stock;
provided, however, that in such case any adjustment that would otherwise be
required then to be made shall be carried forward and shall be made at the time
of and together with the next subsequent adjustment which, together with any
adjustment so carried forward, shall aggregate at least two ($.02) cents for one
(1) share of Common Stock. In addition, Registered Holders shall not be entitled
to cash dividends paid by the Company prior to the exercise of any warrant or
warrants held by them.

                  9. EXCHANGE AND REPLACEMENT OF WARRANT CERTIFICATES. Each
Underwriters' Warrant Certificate is exchangeable without expense, upon the
surrender thereof by the registered Holders at the principal executive office of
the Company, for a new Underwriters' Warrant Certificate of like tenor and date
representing in the aggregate the right to purchase the same number of
Underwriters' Securities in such denominations as shall be designated by the
Holders thereof at the time of such surrender.

                  10. LOSS, THEFT ETC. OF CERTIFICATES Upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft,
destruction or mutilation of any Underwriters' Warrant Certificate, and, in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory
to it, and reimbursement to the Company of all reasonable expenses incidental
thereto, and upon surrender and cancellation of the Underwriters' Warrant
Certificates, if mutilated, the Company will make and deliver a new
Underwriters' Warrant Certificate of like tenor, in lieu thereof.

                  11. ELIMINATION OF FRACTIONAL INTERESTS. The Company shall not
be required to issue certificates representing fractions of shares of Common
Stock upon the exercise of the Underwriters' Warrant, nor shall it be required
to issue scrip or pay cash in lieu of fractional interests; provided, however,
that if a Holder exercises all Underwriters' Warrant held of record by such
Holder the fractional interests shall be eliminated by

<PAGE>

rounding any fraction to the nearest whole number of shares of Common Stock or
other securities, properties or rights.

                  12. RESERVATION AND LISTING OF SECURITIES. The Company shall
at all times reserve and keep available out of its authorized shares of Common
Stock, solely for the purpose of issuance upon the exercise of the Underwriters'
Warrant, such number of shares of Common Stock or other securities and
properties or rights as shall be issuable upon the exercise thereof. The Company
covenants and agrees that, upon exercise of Underwriters' Warrant and payment of
the Purchase Price therefor, all the shares of Common Stock issuable upon such
exercise shall be duly and validly issued, fully paid, non-assessable and not
subject to the preemptive rights of any stockholder. As long as the
Underwriters' Warrant shall be outstanding, the Company shall use its best
efforts to cause the Common Stock to be listed (subject to official notice of
issuance) on all securities exchanges on which the Common Stock issued to the
public in connection herewith may then be listed or quoted.

                  13. NOTICES TO UNDERWRITERS' WARRANT HOLDERS. Nothing
contained in this Agreement shall be construed as conferring upon the Holders
the right to vote or to consent or to receive notice as a stockholder in respect
of any meetings of stockholders for the election of directors or any other
matter, or as having any rights whatsoever as a stockholder of the Company. If,
however, at any time prior to the expiration of the Underwriters' Warrant and
their exercise, any of the following events shall occur:

                           (a) the Company shall take a record of the holders of
its shares of Common Stock for the purpose of entitling them to receive a
dividend or distribution payable otherwise than in cash, or a cash dividend or
distribution payable otherwise than out of current or retained earnings, as
indicated by the accounting treatment of such dividend or distribution on the
books of the Company; or

                           (b) the Company shall offer to all the holders of its
Common Stock any additional shares of capital stock of the Company or securities
convertible into or exchangeable for shares of capital stock of the Company, or
any option, right or warrant to subscribe therefor; or

                           (c) a dissolution, liquidation or winding up of the
Company (other than in connection with a consolidation or merger) or a sale of
all or substantially all of its property, assets and business as an entirety
shall be proposed; then, in any one or more of said events, the Company shall
give written notice of such event at least fifteen (15) calendar days prior to
the date fixed as a record date or the date of closing the transfer books for
the determination of the stockholders entitled to such dividend, distribution,
convertible or exchangeable securities or subscription rights, or entitled to
vote on such proposed dissolution, liquidation, winding up or sale. Such notice
shall specify such record date or the date of closing the transfer books, as the
case may be. Failure to give such notice or any defect therein shall not affect
the validity of any action taken in connection with the declaration or payment
of any such dividend, or the issuance of any convertible or exchangeable
securities, or subscription rights, options or warrants, or any proposed
dissolution, liquidation, winding up or sale.

                  14. NOTICES. All notices, requests, consents and other
communications hereunder shall be in writing and shall be deemed to have been
duly made when delivered, or five days after being mailed by registered or
certified mail, return receipt requested: If to the registered Holders of the
Underwriters' Warrant, to the address of such Holders as shown on the books of
the Company; or

                           (a) If to the Company to 6950 Bryan Dairy Road, Largo
Florida, 33777 or to such other address as the Company may designate by notice
to the Holders, with a courtesy copy to Thomas Rose at Sichenzia, Ross &
Friedman LLP, 135 West 50th Street, 20th Floor, New York, NY 10020.

                  15. SUPPLEMENTS AND AMENDMENTS. The Company and the
Underwriter may from time to time supplement or amend this Agreement without the
approval of any Holders of Underwriters' Warrant Certificates (other than the
Underwriters) in order to cure any ambiguity, to correct or supplement any
provision contained herein which may be defective or inconsistent with any
provisions herein, or to make any other provision in regard to matters or
questions arising hereunder which the Company and the Underwriters may deem
necessary or desirable and which the Company and the Underwriters deem shall not
adversely affect the interests of the Holders

<PAGE>

of Underwriters' Warrant Certificates.

                  16. SUCCESSORS. All the covenants and provisions of this
Agreement shall be binding upon and inure to the benefit of the Company, the
Underwriter, the Holders and their respective successors and assigns hereunder.

                  17. TERMINATION. This Agreement shall terminate at the close
of business on , 2005. Notwithstanding the foregoing, the indemnification
provisions of Section 7 shall survive such termination until the close of
business on the expiration of any applicable statue of limitations.

                  18. GOVERNING LAW; SUBMISSION TO JURISDICTION. This Agreement
and each Underwriters' Warrant Certificate issued hereunder shall be deemed to
be a contract made under the laws of the State of New York and for all purposes
shall be construed in accordance with the laws of said state without giving
effect to the rules of said state governing the conflicts of laws.

                  19. ENTIRE AGREEMENT; MODIFICATION. This Agreement (including
the Underwriting Agreement, to the extent portions thereof are referred to
herein) contains the entire understanding between the parties hereto with
respect to the subject matter hereof and thereof. This Agreement may not be
modified or amended except by a writing duly signed by the Company and the
Holders of a Majority in Interest of the Underwriters' Securities (for this
purpose, treating all then outstanding Underwriters' Warrants as if they had
been exercised).

                  20. SEVERABILITY. If any provision of this Agreement shall be
held to be invalid or unenforceable, such invalidity or unenforceability shall
not affect any other provision of this Agreement.

                  21. CAPTIONS. The caption headings of the Sections of this
Agreement are for convenience of reference only and are not intended, nor should
they be construed as, a part of this Agreement and shall be given no substantive
effect.

                  22. BENEFITS OF THIS AGREEMENT. Nothing in this Agreement
shall be construed to give to any person or corporation other than the Company
and the Underwriter and any other registered Holders of the Underwriters'
Warrant Certificates or Underwriters' Securities any legal or equitable right,
remedy or claim under this Agreement; and this Agreement shall be for the sole
and exclusive benefit of the Company and the Underwriter and any other Holders
of the Underwriters' Warrant Certificates or Underwriters' Securities.

                  23. COUNTERPARTS. This Agreement may be executed in any number
of counterparts and each of such counterparts shall for all purposes be deemed
to be an original, and such counterparts shall together constitute but one and
the same instrument.

                  24. BINDING EFFECT. This Agreement shall be binding upon and
inure to the benefit of the Company, the Underwriters and their respective
successors and assigns and the Holders from time to time of the Underwriters'
Warrant Certificates or any of them.

                          [SIGNATURE ON FOLLOWING PAGE]

<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed, as of the day and year first above written.

                                     GO2PHARMACY, INC.

                                     By:________________________________________
                                     Name:

                                     UTENDAHL CAPITAL PARTNERS, L.P.

                                     By:________________________________________
                                     Name:
                                     Title:

<PAGE>

                                   SCHEDULE A

                                       TO

                         UNDERWRITERS' WARRANT AGREEMENT

                                     BETWEEN

                                GO2PHARMACY, INC.
                                       AND

                         UTENDAHL CAPITAL PARTNERS, L.P.

UNDERWRITER

Utendahl Capital Partners, L.P.

<PAGE>

                                GO2PHARMACY, INC.
                                -----------------

                               WARRANT CERTIFICATE

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933 (THE "ACT"), AND MAY NOT BE OFFERED FOR SALE OR SOLD
EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, OR
(ii) AN OPINION OF COUNSEL, IF SUCH OPINION AND COUNSEL SHALL BE REASONABLY
SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER
THE ACT IS AVAILABLE.

THE TRANSFER OR EXCHANGE OF THE WARRANTS REPRESENTED BY THIS CERTIFICATE IS
RESTRICTED IN ACCORDANCE WITH THE WARRANT AGREEMENT REFERRED TO HEREIN.

                      EXERCISABLE COMMENCING , 2001 THROUGH
                  5:00 P.M., NEW YORK TIME ON September , 2005

                                       Warrant covering 100,000 shares of Common
                                       Stock

No. UW-1

                  This Warrant Certificate certifies that Utendahl Capital
Partners, L.P. or registered assigns, is the registered holder of this Warrant
to purchase initially, at any time from , 2001, until 5:00 p.m., New York time
on , 2005 (the "Expiration Date"), up to 100,000 shares of Common Stock, $.01
par value (the "Common Stock") of Go2Pharmacy, Inc. ("Company") exercisable to
purchase one share of Common Stock at a purchase price of $13.20 per share (165%
of the per share public offering price) (the "Purchase Price"), upon the
surrender of this Warrant Certificate and payment of the applicable Purchase
Price at an office or agency of the Company, but subject to the conditions set
forth herein and in the Underwriters' Warrant Agreement, dated as of , 2000, by
and between the Company and Utendahl Capital Partners, L.P. (the "Warrant
Agreement"). Payment of the Purchase Price shall be made by certified or
cashier's check or money order payable to the order of the Company or through
the surrender of the Company's securities.

                  No Warrant may be exercised after 5:00 p.m., New York time, on
the Expiration Date, at which time all Warrant evidenced hereby, unless
exercised prior thereto, shall thereafter be void.

                  The Warrant evidenced by this Warrant Certificate is part of a
duly authorized issue of Warrants issued pursuant to the Warrant Agreement
between the Company and the Underwriter, which Warrant Agreement is hereby
incorporated by reference in and made a part of this instrument and is hereby
referred to for a description of the rights, limitation of rights, obligations,
duties and immunities thereunder of the Company and the holders (the words
"holders" or "holder" meaning the registered holders or registered holder) of
the Warrant.

                  The Warrant Agreement provides that upon the occurrence of
certain events the Purchase Price and the type and/or number of the Company's
securities issuable upon the exercise of this Warrant, may, subject to certain
conditions, be adjusted. In such event, the Company will, at the request of the
holder, issue a new Warrant Certificate evidencing the adjustment in the
Purchase Price and the number and/or type of securities issuable upon the
exercise of the Warrant; provided, however, that the failure of the Company to
issue such new Warrant Certificates shall not in any way change, alter, or
otherwise impair, the rights of the holder as set forth in the Warrant
Agreement.

                  Upon due presentment for registration of transfer of this
Warrant Certificate at an office or agency of the Company, a new Warrant
Certificate or Warrant Certificates of like tenor and evidencing in the
aggregate a like number of Warrant shall be issued to the transferee(s) in
exchange as provided herein, without any charge

<PAGE>

except for any tax or other governmental charge imposed in connection with such
transfer.

                  Upon the exercise of less than all of the Warrants evidenced
by this Certificate, the Company shall forthwith issue to the holder hereof a
new Warrant Certificate representing such number of unexercised Warrants.

                  The Company may deem and treat the registered holder(s) hereof
as the absolute owner(s) of this Warrant Certificate (notwithstanding any
notation of ownership or other writing hereon made by anyone), for the purpose
of any exercise hereof, and of any distribution to the holder(s) hereof, and for
all other purposes, and the Company shall not be affected by any notice to the
contrary.

                  All terms used in this Warrant Certificate which are defined
in the Warrant Agreement shall have the meanings assigned to them in the Warrant
Agreement.

                  IN WITNESS WHEREOF, the undersigned has executed this
certificate this day of , 2000.

                                          GO2PHARMACY, INC.

                                          By:___________________________________

ATTEST:

By:__________________________________

<PAGE>

                               FORM OF ASSIGNMENT

             (To be executed by the registered holder if such holder
                 desires to transfer the Warrant Certificate.)

                  FOR VALUE RECEIVED___________________________
hereby sells, assigns and transfers unto _____________________

                  (Please print name and address of transferee)

this Warrant Certificate, together with all right, title and interest therein,
and does hereby irrevocably constitute and appoint _____________________
Attorney, to transfer the within Warrant Certificate on the books of
GO2PHARMACY, INC. with full power of substitution.

Dated:

                    Signature_____________________

                    (Signature must conform in all respects to the name of
                    holder as specified on the face of the Warrant Certificate.)

[Signature guarantee]                           ________________________________
                                                (Insert Social Security or Other
                                                 Identifying Number of Holders)

<PAGE>

                          FORM OF ELECTION TO PURCHASE

The undersigned hereby irrevocably elects to exercise the right, represented by
this Warrant Certificate, to purchase ______ shares of Common Stock and herewith
tenders in payment for such securities a certified or cashier's check or money
order payable to the order of Go2Pharmacy, Inc. in the amount of $______, all in
accordance with the terms hereof. The undersigned requests that certificates for
such securities be registered in the name of ___________________________ whose
address is _____________________ and that such certificates be delivered to
_____________________________________ whose address is
____________________________________________________________.

Dated:

Signature_______________________

(Signature must conform in all respects to the name of holder as specified on
the face of the Warrant Certificate.)

(Insert Social Security or Other
Identifying Number of Holders)

[Signature guarantee]EXHIBIT 4.3

                    ADVISORY AND INVESTMENT BANKING AGREEMENT

                  This Agreement is made and entered into as of the [__]th day
of [____], 2000 by and between Utendahl Capital Partners, L.P., a New York
Limited Partnership ("Utendahl") and Go2Pharmacy, Inc., a Florida corporation
(the "Company").

                  In consideration of the mutual promises made herein and for
other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereto agree as follows:

                  1. PURPOSE: The Company hereby engages Utendahl for the term
specified in Paragraph 2 hereof to render consulting advice to the Company as an
investment banker relating to financial and similar matters upon the terms and
conditions set forth herein.

                  2. TERM: Except as otherwise specified in paragraph 4 hereof,
this Agreement shall be effective from [THE EFFECTIVE DATE] to [36 months
thereafter].

                  3. DUTIES OF UTENDAHL: During the term of this Agreement,
Utendahl shall seek out Transactions (as hereinafter defined) on behalf of the
Company and shall furnish advice to the Company in connection with any such
Transactions.

                  4. COMPENSATION: In consideration for the services rendered by
Utendahl to the Company pursuant to this Agreement (and in addition to the
expenses provided for in Paragraph 5 hereof), the Company shall compensate
Utendahl as follows:

                           (a) The Company shall pay Utendahl a fee of $4,027.77
per month during the term of this Agreement. The sum of $145,000 shall be
payable in full on the date of this Agreement.

<PAGE>

                           (b) In the event that any Transaction (as hereinafter
defined) occurs during the term of this Agreement or one year thereafter, the
Company shall pay fees to Utendahl as follows:

         (i)      five percent (5%) of any consideration up to and including
                  $1,000,000 paid pursuant to the Transaction, plus

         (ii)     four percent (4%) of any consideration from $1,000,001 up to
                  and including $2,000,000 paid pursuant to the Transaction,
                  plus

         (iii)    three percent (3%) of any consideration from $2,000,001 up to
                  and including $3,000,000 paid pursuant to the Transaction,
                  plus

         (iv)     two percent (2%) of any consideration from $3,000,001 up to
                  and including $4,000,000 paid pursuant to the Transaction,
                  plus

         (v)      one percent (1%) of any consideration greater than $4,000,000
                  paid pursuant to the Transaction.

                           For the purposes of this Agreement, "Consideration"
shall mean the total market value on the day of the closing of stock, cash,
assets and all other property (real or personal) exchanged or received, directly
or indirectly by the Company or any of its security holders in connection with
any Transaction. Any co-broker or brokers retained by Utendahl shall be paid by
Utendahl.

                           For the purposes of the Agreement, a "Transaction"
shall mean (a) any transaction originated by Utendahl, whereby, directly or
indirectly, control of or a material interest in the Company or any of its
businesses or any of their respective assets, is transferred for Consideration,
or (b) any transaction originated by Utendahl whereby the Company acquires any
other company or the assets of any other company or an interest in any other
company (an "Acquisition") or to so act.

                                       2
<PAGE>

                           In the event Utendahl originates a line of credit
with a lender, the Company and Utendahl will mutually agree on a satisfactory
fee for such services provided based upon reasonable and customary practice in
the industry and the terms of payment of such fee; provided, however, that in
the event the Company is introduced to a corporate partner by Utendahl in
connection with a merger, Acquisition or financing and a credit line develops
directly as a result of the introduction, the appropriate fee shall be the
amount set forth in the schedule above with consideration to be based upon the
amount of the line of credit. In the event Utendahl introduces the Company to a
joint venture partner or customer and sales develop as a result of the
introduction, the Company agrees to pay a fee of five percent (5%) of total
sales generated directly from this introduction during the first two years
following the date of the first sale, in lieu of the fees set forth in the
schedule above. Total sales shall mean cash receipts less any applicable
refunds, returns, allowances, credits and shipping charges and monies paid by
the Company by way of settlement or judgment arising out of claims made by or
threatened against the Company. Commission payments shall be paid on the 15th
day of each month following the receipt of customers' payment. In the event any
adjustments are made to the total sales after the commission has been paid, the
Company shall be entitled to an appropriate refund or credit against future
payments under this Agreement. All fees to be paid pursuant to this Agreement,
except as otherwise specified, are due and payable to Utendahl in cash at the
closing or closings of any transaction specified in Paragraph 4 hereof. In the
event that this Agreement shall not be renewed or if terminated for any reason,
notwithstanding any such non-renewal or termination, Utendahl shall be entitled
to a full fee as provided under Paragraphs 4 and 5 hereof, for any transaction
for which the discussions were initiated during the term of this Agreement and
which is consummated within a period of twelve months after non-renewal or
termination of this Agreement.

                                       3
<PAGE>

                  5. EXPENSES OF UTENDAHL: In addition to the fees payable
hereunder, and regardless of whether any transaction set forth in Paragraph 4
hereof is proposed or consummated the Company shall reimburse Utendahl for all
fees and disbursements of Utendahl's counsel and Utendahl's travel and
reasonable out-of-pocket expenses incurred in connection with and in direct
furtherance of the services performed by Utendahl pursuant to this Agreement,
including without limitation, hotels, food and associated expenses and
long-distance telephone calls. Utendahl shall obtain the consent of the Company
before incurring any expense over $1,000.

                  6. LIABILITY OF UTENDAHL:

                           (a) The Company acknowledges that all opinions and
advice (written or oral) given by Utendahl to the Company in connection with
Utendahl's engagement are intended solely for the benefit and use of the Company
in considering the transaction to which they relate, and the Company agrees that
no person or entity other than the Company shall be entitled to make use of or
rely upon the advice of Utendahl to be given hereunder, and no such opinion or
advice shall be used for any other purpose or reproduced, disseminated, quoted
or referred to at any time, in any manner or for any purpose, nor may the
Company make any public references to Utendahl, or use Utendahl's name in any
annual reports or any other reports or releases of the Company without
Utendahl's prior written consent.

                           (b) The Company acknowledges that Utendahl makes no
commitment whatsoever as to making a market in the Company's securities or to
recommending or advising its clients to purchase the Company's securities,
except that Utendahl has committed to make a market in the Company's securities
for at least 45 days after the effective date of the Company's initial public
offering. Research reports or corporate finance reports that may be prepared by
Utendahl will, when and if

                                       4
<PAGE>

prepared, be done solely on the merits or judgment of analysis of Utendahl or
any senior corporate finance personnel of Utendahl.

                  7. UTENDAHL'S SERVICES TO OTHERS: The Company acknowledges
that Utendahl or its affiliates are in the business of providing financial
services and consulting advice to others. Nothing herein contained shall be
construed to limit or restrict Utendahl in conducting such business with respect
to others, or in rendering such advice to others.

                  8.   COMPANY INFORMATION:

                           (a) The Company recognizes and confirms that, in
advising the Company and in fulfilling its engagement hereunder, Utendahl will
use and rely on data, material and other information furnished to Utendahl by
the Company. The Company acknowledges and agrees that in performing its services
under this engagement, Utendahl may rely upon the data, material and other
information supplied by the Company without independently verifying the
accuracy, completeness or veracity of same.

                           (b) Except as contemplated by the terms hereof or as
required by applicable law, Utendahl shall keep confidential all material
non-public information provided to it by the Company, and shall not disclose
such information to any third party, other than such of its employees and
advisors as Utendahl determines to have a need to know. Upon termination of this
Agreement, at the request of the Company, Utendahl shall deliver to the Company
all non-public material in its possession relating to the business affairs of
the Company.

                                       5
<PAGE>

                  9.  INDEMNIFICATION:

                           (a) The Company shall indemnify and hold Utendahl and
its directors, officers, employees and agents harmless against any and all
liabilities, claims, lawsuits, including any and all awards and/or judgments to
which it may become subject under the Securities Act of 1933, as amended (the
"1933 Act"), the Securities Exchange Act of 1934, as amended (the "Act") or any
other federal or state statute, at common law or otherwise, insofar as said
liabilities, claims and lawsuits (including awards and/or judgments) arise out
of or are in connection with the services rendered by Utendahl or any
transactions in connection with this Agreement, except for any liabilities,
claims and lawsuits (including awards judgments and related costs and expenses),
arising out of acts or omissions of Utendahl. In addition, the Company shall
also indemnify and hold Utendahl harmless against any and all reasonable costs
and expenses, including reasonable counsel fees, incurred or relating to the
foregoing. If it is finally judicially determined that the Company will not be
responsible for any liabilities, claims and lawsuits or expenses related
thereto, the indemnified party, by his or its acceptance of such amounts, agrees
to repay the Company all amounts previously paid by the Company to the
indemnified person and will pay all costs of collection thereof, including but
not limited to reasonable attorneys' fees related thereto.

                           Utendahl shall give the Company prompt notice of any
such liability, claim or lawsuit which Utendahl contends is the subject matter
of the Company's indemnification and the Company thereupon shall be granted the
right to take any and all necessary and proper action, at its sole cost and
expense, with respect to such liability, claim and lawsuit, including the right
to settle, compromise and dispose of such liability, claim or lawsuit, excepting
therefrom any and all proceedings or hearings before any regulatory bodies
and/or authorities.

                                       6
<PAGE>

                           Utendahl shall indemnify and hold the Company and its
directors, officers, employees and agents harmless against any and all
liabilities, claims and lawsuits, including any and all awards and/or judgments
to which it may become subject under the 1933 Act, the Act or any other federal
or state statute, at common law or otherwise, insofar as said liabilities,
claims and lawsuits (including awards and/or judgments) arise out of or are
based upon Utendahl's gross negligence, willful misconduct, bad faith or any
untrue statement or alleged untrue statement of a material fact or omission at a
material fact required to be stated or necessary to make the statement provided
by Utendahl, not misleading, which statement or omission was made in reliance
upon information furnished in writing to the Company by or on behalf of Utendahl
for inclusion in any registration statement or prospectus or any amendment or
supplement thereto in connection with any transaction to which this Agreement
applies. In addition, Utendahl shall also indemnify and hold the Company
harmless against any and all costs and expenses, including reasonable counsel
fees, incurred or relating to the foregoing.

                           The Company shall give to Utendahl prompt notice of
any such liability, claim or lawsuit which the Company contends is the subject
matter of Utendahl's indemnification and Utendahl thereupon shall be granted the
right to a take any and all necessary and proper action, at its sole cost and
expense, with respect to such liability, claim and lawsuit, including the right
to settle, compromise or dispose of such liability, claim or lawsuit, excepting
therefrom any and all proceedings or hearings before any regulatory bodies
and/or authorities.

                           (b) In order to provide for just and equitable
contribution under the Act in any case in which (i) any person entitled to
indemnification under this Section 9 makes claim for indemnification pursuant
hereto but it is judicially determined (by the entry of a final judgment or
decree by a court of competent jurisdiction and the expiration of time to appeal
or the denial of the last right of

                                       7
<PAGE>

appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section 9 provides for indemnification in
such case, or (ii) contribution under the Act may be required on the part of any
such person in circumstances for which indemnification is provided under this
Section 9, then, and in each such case, the Company and Utendahl shall
contribute to the aggregate losses, claims, damages or liabilities to which they
may be subject (after any contribution from others) in such proportion taking
into consideration the relative benefits received by each party from the
offering covered by the prospectus with respect to any transactions in
connection with this Agreement (taking into account the portion of the proceeds
of the offering realized by each), the parties' relative knowledge and access to
information concerning the matter with respect to which the claim was assessed,
the opportunity to correct and prevent any statement or omission and other
equitable considerations appropriate under the circumstances; provided, however,
that notwithstanding the above in no event shall Utendahl be required to
contribute any amount in excess of 10% of the public offering price of any
securities to which such Prospectus applies; and provided, that, in any such
case, no person guilty of a fraudulent misrepresentation (within the meaning of
Section 11(f) of the Act) shall be entitled to contribution from any person who
was not guilty of such fraudulent misrepresentation.

                           Within fifteen (15) days after receipt by any party
to this Agreement (or its representative) of notice of the commencement of any
action, suit or proceeding, such party will, if a claim for contribution in
respect thereof is to be made against another party (the "Contributing Party"),
notify the Contributing Party of the commencement thereof, but the omission so
to notify the Contributing Party will not relieve it from any liability which it
may have to any other party other than for contribution hereunder. In case any
such action, suit or proceeding is brought against any party, and such party
notifies a Contributing Party or his or its representative of the commencement
thereof within

                                       8
<PAGE>

the aforesaid fifteen (15) days, the Contributing Party will be entitled to
participate therein with the notifying party and any other Contributing Party
similarly notified. Any such Contributing Party shall not be liable to any party
seeking contribution on account of any settlement of any claim, action or
proceeding effected by such party seeking contribution without the written
consent of the Contributing Party. The indemnification provisions contained in
this Section 9 are in addition to any other rights or remedies which either
party hereto may have with respect to the other or hereunder.

                  10. UTENDAHL AS INDEPENDENT CONTRACTOR : Utendahl shall
perform its services hereunder as independent contractors and not as employees
of the Company or an affiliate thereof. It is expressly understood and agreed to
by the parties hereto that Utendahl shall have no authority to act for,
represent or bind the Company or any affiliate thereof in any manner, except as
may be agreed to expressly by the Company in writing from time to time.

                  11. MISCELLANEOUS:

                           (a) This Agreement between the Company and Utendahl
constitutes the entire agreement and understanding of the parties hereto, and
supersedes any and all previous agreements and understandings, whether oral or
written, between the parties with respect to the matters set forth herein.

                           (b) Any notice or communication permitted or required
hereunder shall be in writing and shall be deemed sufficiently given if
hand-delivered or sent (i) postage prepaid by registered mail, return receipt
requested, or (ii) by facsimile, to the respective parties as set forth below,
or to such other address as either party may notify the other in writing:

         If to the Company, to:     Go2Pharmacy, Inc.
                                    6950 Bryan Dairy Road
                                    Largo, FL 33777
                                    Attn: Dr. Kotha S. Sekharam

         with a copy to:            Sichenzia, Ross & Freidman LLP

                                       9
<PAGE>

                                    135 West 50th Street, 20th Floor
                                    New York, New York 10020
                                    Attn: Gregory Sichenzia, Esq.

         If to Utendahl, to:        Utendahl Capital Partners, L.P.
                                    30 Broad Street, 21st Floor
                                    New York, NY 10004
                                    Attn: LeRoy Watkins

         with a copy to:            Gersten, Savage & Kaplowitz, LLP
                                    101 East 52nd Street, 9th Floor
                                    New York, New York 10022
                                    Attn: Jay M. Kaplowitz

                           (c) This Agreement shall be binding upon and inure to
the benefit of each of the parties hereto and their respective successors, legal
representatives and assigns.

                           (d) This Agreement may be executed in any number of
counterparts, each of which together shall constitute one and the same original
document.

                           (e) No provision of this Agreement may be amended,
modified or waived, except in a writing signed by all of the parties hereto.

                           (f) This Agreement shall be construed in accordance
with and governed by the laws of the State of New York, without giving effect to
conflict of law principles. The parties hereby agree that any dispute which may
arise between them arising out of or in connection with this Agreement shall be
adjudicated before a court located in New York County, and they hereby submit to
the exclusive jurisdiction of the courts of the State of New York located in New
York County and of the federal courts in the Southern District of New York with
respect to any action or legal proceeding commenced by any party, and
irrevocably waive any objection they now or hereafter may have respecting the
venue of any such action or proceeding brought in such a court or respecting the
fact that such court is an inconvenient

                                       10
<PAGE>

forum, relating to or arising out of this Agreement, and consent to the service
of process in any such action or legal proceeding by means of registered or
certified mail, return receipt requested, in care of the address set forth in
Paragraph 11(b) hereof.

                  IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be duly executed, as of the day and year first above written.

                                        UTENDAHL CAPITAL PARTNERS, L.P.

                                        By:________________________________

                                        GO2PHARMACY, INC.

                                        By:________________________________

                                       11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]